Diagnostic approaches and potential therapeutic options for coronavirus disease 2019
- PMID: 33014380
- PMCID: PMC7525249
- DOI: 10.1016/j.nmni.2020.100770
Diagnostic approaches and potential therapeutic options for coronavirus disease 2019
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of China in late December 2019 and identified as a novel coronavirus. Due to its contagious nature, the virus spreads rapidly and causes coronavirus disease 2019 (COVID-19). The global tally of COVID-19 was 28 million in early September 2020. The fears and stress associated with SARS-CoV-2 has demolished the socio-economic status worldwide. Researchers are trying to identify treatments, especially antiviral drugs and/or vaccines, that could potentially control the viral spread and manage the ongoing unprecedented global crisis. To date, more than 300 clinical trials have been conducted on various antiviral drugs, and immunomodulators are being evaluated at various stages of COVID-19. This review aims to collect and summarize a list of drugs used to treat COVID-19, including dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide and ivermectin. However, some of these drugs are not effective and their use has been suspended by WHO.
Keywords: 2019-nCoV; Coronavirus 2019; WHO; drugs; global tally; severe acute respiratory syndrome coronavirus 2.
© 2020 The Authors.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7578268/bin/gr1.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7578268/bin/gr3.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7578268/bin/gr2.gif)
Similar articles
-
Safety profile of COVID-19 drugs in a real clinical setting.Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28. Eur J Clin Pharmacol. 2022. PMID: 35088108 Free PMC article. Review.
-
A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.Front Pharmacol. 2021 Feb 26;11:590154. doi: 10.3389/fphar.2020.590154. eCollection 2020. Front Pharmacol. 2021. PMID: 33815095 Free PMC article. Review.
-
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24. Biomed Pharmacother. 2020. PMID: 32861965 Free PMC article. Review.
-
A global treatments for coronaviruses including COVID-19.J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11. J Cell Physiol. 2020. PMID: 32394467 Free PMC article. Review.
-
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117. Curr Med Chem. 2020. PMID: 32297571
Cited by
-
Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination?Clin Immunol Commun. 2022 Dec;2:1-5. doi: 10.1016/j.clicom.2021.12.002. Epub 2021 Dec 23. Clin Immunol Commun. 2022. PMID: 38620684 Free PMC article. Review.
-
A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19.Front Microbiol. 2022 Jul 14;13:927306. doi: 10.3389/fmicb.2022.927306. eCollection 2022. Front Microbiol. 2022. PMID: 35910658 Free PMC article. Review.
-
Biologically Relevant Micellar Nanocarrier Systems for Drug Encapsulation and Functionalization of Metallic Nanoparticles.Nanomaterials (Basel). 2022 May 20;12(10):1753. doi: 10.3390/nano12101753. Nanomaterials (Basel). 2022. PMID: 35630975 Free PMC article.
-
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview.Vaccines (Basel). 2021 Nov 12;9(11):1317. doi: 10.3390/vaccines9111317. Vaccines (Basel). 2021. PMID: 34835248 Free PMC article. Review.
-
Allium sativum derived carbon dots as a potential theranostic agent to combat the COVID-19 crisis.Sens Int. 2021;2:100102. doi: 10.1016/j.sintl.2021.100102. Epub 2021 May 29. Sens Int. 2021. PMID: 34766058 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous